Preferred Label : ixekizumab;

MeSH note : a humanized anti-interleukin-17 monoclonal antibody for treatment of psoriasis;

CISMeF synonym : LY2439821;

MeSH hyponym : LY-2439821;

Is substance : O;

UNII : BTY153760O;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3478092/fr/taltz-ixekizumab-psoriasis-en-plaques-pediatrique
2024
false
false
false
France
evaluation of the transparency committee
Patch
Pediatric
bone plates
psoriasis
Taltz
Childhood-Onset Systemic Lupus Erythematosus
pediatrics
psoriasis vulgaris
Ixekizumab
ixekizumab
Psoriasis
Pediatricians
ixekizumab
pediatrician
Pediatric

---
https://www.has-sante.fr/jcms/p_3363293/fr/taltz-ixekizumab-psoriasis-en-plaques-de-l-adulte
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
dermatologic agents
psoriasis
ixekizumab
ixekizumab
adult
injections, subcutaneous
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3271027/fr/taltz-ixekizumab-rhumatisme-psoriasique
2021
false
false
false
France
evaluation of the transparency committee
ixekizumab
Taltz
antibodies, monoclonal, humanized
ixekizumab
treatment outcome
arthritis, psoriatic
ixekizumab
Interleukin-17
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3211088/fr/taltz-spondyloarthrite-axiale
2020
false
false
false
France
insurance, health, reimbursement
ixekizumab
ixekizumab
treatment outcome
spondylitis, ankylosing
adult
Non-radiographic axial spondyloarthritis
Non-radiographic axial spondyloarthritis (disorder)
guidelines for drug use
Interleukin-17
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/portail/jcms/c_2847914/fr/taltz-ixekizumab-immunosuppresseur-anti-interleukine-17a
2018
false
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
ixekizumab
ixekizumab
injections, subcutaneous
treatment outcome
immunosuppressive agents
immunosuppressive agents
Interleukin-17A
Interleukin-17A
arthritis, psoriatic
drug therapy, combination
adult
insurance, health, reimbursement
ixekizumab
Taltz
Interleukin-17
Interleukin-17
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
http://www.has-sante.fr/portail/jcms/c_2678850/fr/taltz
http://www.has-sante.fr/portail/jcms/c_2678850/fr/taltz-ixekizumab-immunosuppresseur-inhibiteur-de-l-interleukine-il-17a
2016
false
false
false
France
French
ixekizumab
antibodies, monoclonal, humanized
psoriasis
treatment outcome
adult
injections, subcutaneous
Interleukin-17
Interleukin-17A
Interleukin-17
Interleukin-17A
evaluation of the transparency committee
insurance, health, reimbursement
chronic disease
ixekizumab
guidelines for drug use
ixekizumab
antibodies, monoclonal, humanized

---
https://www.ema.europa.eu/medicines/human/EPAR/Taltz
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ixekizumab
antibodies, monoclonal, humanized
drug approval
europe
psoriasis
treatment outcome
adult
injections, subcutaneous
Interleukin-17
Interleukin-17A
Interleukin-17
Interleukin-17A
product surveillance, postmarketing
drug interactions
contraception
pregnancy
breast feeding
drug evaluation, preclinical
ixekizumab
ixekizumab
antibodies, monoclonal, humanized

---
Nous contacter.
01/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.